Company: LNAI
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001731122-25-001544
Chunk: 34

Company: Lunai Bioworks Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
822
)

Prepaid & Other Assets

17,405

Fixed Assets

13,365

Total Assets Acquired:

26,948

Accounts Payable

975

Accrued Expenses

7,594

Other Current Liabilities

73,879

Total Liabilities Assumed

82,448

Net Assets Acquired

(55,500
)

Software

143,000

Trade Name

8,000

Goodwill

5,963,000

Total Consideration
 
$
6,058,500

The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the goodwill is expected
to be deductible for income tax purposes.

The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.

Consolidated unaudited pro forma information: 

The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
three-month period ended September 30, 2024. These amounts have been estimated after applying the Company’s accounting policies:

Schedule of statement of operations

Revenues
 
$
318,918

Net loss
 
$
(44,499,586
)

The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.

    23

NOTE 11 — SUBSEQUENT EVENTS 

On November 4, 2025, the Company
issued 20,000 shares of Common Stock for consulting services valued at $16,680.

On October 30, 2025, the Company
cancelled 25,000 shares of Common Stock upon termination, previously issued to the former Chief Executive Officer of Renovaro Cube
valued at $177,500.

On October 29, 2025, the Company
issued 237,500 shares of Common Stock pursuant to a settlement agreement valued at $228,000.

On October 17, 2025, the Company
issued 20,000 shares of Common Stock for consulting services valued at $24,000.

24

Item 2. Management’s Discussion and Analysis of Financial Condition
and Results